Institut Regional du Cancer de Montpellier
- Research works
- 91 ▼ 40% vs 2013–17
- Citations
- 2k 22.3 per fractional work
- Top-10% rate
- 17.0% record average 16.5%
- Open access
- 54% world 28%
Not ranked overall: Institut Regional du Cancer de Montpellier is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 4.9×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 4.9×
- Medicine 3.3×
- Immunology and Microbiology 1.9×
- Pharmacology, Toxicology and Pharmaceutics 0.9×
- Physics and Astronomy 0.8×
- Mathematics 0.5×
- Health Professions 0.5×
- Nursing 0.4×
- Chemistry 0.2×
- Agricultural and Biological Sciences 0.1×
- Environmental Science 0.1×
- Decision Sciences 0.1×
- Economics, Econometrics and Finance 0.1×
- Neuroscience 0.1×
- Computer Science 0.1×
- Psychology 0.1×
- Social Sciences 0.1×
- Engineering 0.0×
Which keywords describe research at Institut Regional du Cancer de Montpellier?
By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Targeted Therapy, Neoadjuvant Therapy, Clinical Practice Guidelines, Radiotherapy, Clinical Trials and Breast Cancer.
- Fluorouracil
- Radioimmunotherapy
- Ovarian Cancer
- Mutational Signatures
- Image-Guided Radiotherapy
- Cancer Genomics
- Cytoreductive Surgery
- Cancer Risk
- Gene Expression
- PET Imaging
- Cetuximab
- Prognostic Factors
- Molecular Subtypes
- Metastasis
- Survival Analysis
- Clinical Trials
- Cancer
- Quality of Life
- Clinical Practice Guidelines
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Neoadjuvant Therapy
- Radiotherapy
- Breast Cancer
- Dosimetry
- Tumor Microenvironment
- Biomarkers
- Precision Medicine
- Cancer Treatment
- Genomic Instability
- Adjuvant Chemotherapy
- BRAF Mutation
- Metastatic Breast Cancer
- Tumor Markers
- Cell-Free DNA
- Molecular Characterization
- Radiotherapy Physics
- Prognostic Markers
- Radiopharmaceuticals
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy13▲ 20×21 topics
- Immunotherapy7▲ 12×15 topics
- Targeted Therapy7▲ 34×5 topics
- Clinical Practice Guidelines6▲ 12×10 topics
- Neoadjuvant Therapy6▲ 30×5 topics
- Quality of Life6▲ 4.8×16 topics
- Radiotherapy5▲ 16×12 topics
- Cancer5▲ 4.1×25 topics
- Breast Cancer5▲ 19×9 topics
- Clinical Trials5▲ 8.7×11 topics
- Dosimetry5▲ 55×2 topics
- Survival Analysis5▲ 19×7 topics
- Tumor Microenvironment4▲ 14×7 topics
- Metastasis4▲ 14×10 topics
- Biomarkers4▲ 7.3×10 topics
- Molecular Subtypes4▲ 51×2 topics
- Precision Medicine3▲ 12×5 topics
- Prognostic Factors3▲ 7.9×14 topics
- Cancer Treatment3▲ 12×5 topics
- Cetuximab3▲ 39×2 topics
- Genomic Instability3▲ 25×3 topics
- PET Imaging3▲ 15×4 topics
- Adjuvant Chemotherapy3▲ 42×2 topics
- Gene Expression3▲ 5.1×9 topics
- BRAF Mutation3▲ 41×2 topics
- Cancer Risk3▲ 11×6 topics
- Metastatic Breast Cancer3▲ 43×2 topics
- Cytoreductive Surgery2▲ 43×2 topics
- Tumor Markers2▲ 39×2 topics
- Cancer Genomics2▲ 48×1 topic
- Cell-Free DNA2▲ 29×2 topics
- Image-Guided Radiotherapy2▲ 51×1 topic
- Molecular Characterization2▲ 14×5 topics
- Mutational Signatures2▲ 48×1 topic
- Radiotherapy Physics2▲ 51×1 topic
- Ovarian Cancer2▲ 28×2 topics
- Prognostic Markers2▲ 27×3 topics
- Radioimmunotherapy2▲ 60×1 topic
- Radiopharmaceuticals2▲ 60×1 topic
- Fluorouracil2▲ 71×1 topic
Which research topics does Institut Regional du Cancer de Montpellier publish most on?
By volume in 2022–2025: Radiopharmaceutical Chemistry and Applications, Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy and Cancer Immunotherapy and Biomarkers.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 1 works
- 2 Ovarian cancer diagnosis and treatment Reproductive Medicine 1 works
- 3 PARP inhibition in cancer therapy Oncology 1 works
- 4 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 5 Cancer Genomics and Diagnostics Cancer Research 0 works
- 6 Thyroid Cancer Diagnosis and Treatment Endocrinology, Diabetes and Metabolism 0 works
- 7 Lung Cancer Research Studies Oncology 0 works
- 8 Colorectal and Anal Carcinomas Surgery 0 works
- 9 Cancer Cells and Metastasis Oncology 0 works
- 10 Neuroendocrine Tumor Research Advances Epidemiology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Institut Regional du Cancer de Montpellier's research output changed?
Output in 2018–2022 was 40% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Montpellier
- Université de Montpellier
- Université Paul-Valéry Montpellier
- Centre Hospitalier Universitaire de Montpellier
- Laboratoire d'Informatique, de Robotique et de Microélectronique de Montpellier
- Hôpital Lapeyronie
- École Nationale Supérieure de Chimie de Montpellier
- Hôpital Saint Eloi
- Hôpital Arnaud de Villeneuve
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.